Adrian Quartel was appointed as our Chief Medical Officer in February 2022. He previously oversaw all scientific and medical functions as Chief Medical Officer at Adamas Pharmaceuticals from September 2020 to February 2022. Prior to Adamas Pharmaceuticals, Dr. Quartel served in various positions at BioMarin Pharmaceuticals Inc., including as Group Vice President, Global Medical Affairs from June 2017 to September 2020 and as Vice President, Medical Affairs, Americas from February 2016 to June 2017. Earlier in his career, Dr. Quartel held senior medical leadership roles where he was responsible for clinical development, pharmacovigilance, and medical affairs at Chiltern, at Astellas, and at ICON Clinical Research. Dr. Quartel worked as a clinical research fellow at UCLA Cedar Sinai and as a resident in cardio-thoracic surgery at Erasmus University Medical Center. Dr. Quartel received an M.D. from Erasmus University Medical School, Rotterdam, in the Netherlands, and a post graduate specialization in pharmaceutical medicine from the Faculty of Pharmaceutical Medicine in London. He is board certified by the General Medical Council (GMC) in pharmaceutical medicine in the United Kingdom.
